155 related articles for article (PubMed ID: 18584778)
1. Skin lesions and mast cells.
Blood; 2008 Jul; 112(1):28. PubMed ID: 18584778
[No Abstract] [Full Text] [Related]
2. Imatinib mesylate in the treatment of systemic mastocytosis: a phase II trial.
Droogendijk HJ; Kluin-Nelemans HJ; van Doormaal JJ; Oranje AP; van de Loosdrecht AA; van Daele PL
Cancer; 2006 Jul; 107(2):345-51. PubMed ID: 16779792
[TBL] [Abstract][Full Text] [Related]
3. [Systemic mastocytosis without the typical mutation of codon 816 successfully treated with imatinib].
Hirayama Y; Konuma Y; Kohda K; Ando M; Obata M; Ueno Y; Sasagawa Y; Wada Y; Shirao S
Nihon Naika Gakkai Zasshi; 2008 Oct; 97(10):2542-5. PubMed ID: 19051746
[No Abstract] [Full Text] [Related]
4. Role of imatinib in the treatment of pediatric onset indolent systemic mastocytosis: a case report.
Agarwala MK; George R; Mathews V; Balasubramanian P; Thomas M; Nair S
J Dermatolog Treat; 2013 Dec; 24(6):481-3. PubMed ID: 23659595
[TBL] [Abstract][Full Text] [Related]
5. A novel form of mastocytosis associated with a transmembrane c-kit mutation and response to imatinib.
Akin C; Fumo G; Yavuz AS; Lipsky PE; Neckers L; Metcalfe DD
Blood; 2004 Apr; 103(8):3222-5. PubMed ID: 15070706
[TBL] [Abstract][Full Text] [Related]
6. Successful treatment of KIT D816V-positive, imatinib-resistant systemic mastocytosis with interferon-alpha.
Yoshida C; Takeuchi M; Tsuchiyama J; Sadahira Y
Intern Med; 2009; 48(22):1973-8. PubMed ID: 19915299
[TBL] [Abstract][Full Text] [Related]
7. On being metachromatic: mystique and misunderstanding in mastocytosis.
Gotlib J
Am J Hematol; 2009 Dec; 84(12):779-81. PubMed ID: 19899132
[No Abstract] [Full Text] [Related]
8. Familial systemic mastocytosis with germline KIT K509I mutation is sensitive to treatment with imatinib, dasatinib and PKC412.
de Melo Campos P; Machado-Neto JA; Scopim-Ribeiro R; Visconte V; Tabarroki A; Duarte AS; Barra FF; Vassalo J; Rogers HJ; Lorand-Metze I; Tiu RV; Costa FF; Olalla Saad ST; Traina F
Leuk Res; 2014 Oct; 38(10):1245-51. PubMed ID: 25139846
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic challenge during the long-term follow-up of a patient with indolent systemic mastocytosis with extensive cutaneous involvement.
Marton I; Pósfai É; Borbényi Z; Bödör C; Papp G; Demeter J; Korom I; Varga E; Bata-Csörgő Z
Eur Rev Med Pharmacol Sci; 2015; 19(9):1607-9. PubMed ID: 26004600
[TBL] [Abstract][Full Text] [Related]
10. Kit Mutations: New Insights and Diagnostic Value.
Falchi L; Verstovsek S
Immunol Allergy Clin North Am; 2018 Aug; 38(3):411-428. PubMed ID: 30007460
[TBL] [Abstract][Full Text] [Related]
11. Imatinib for systemic mast-cell disease.
Pardanani A; Elliott M; Reeder T; Li CY; Baxter EJ; Cross NC; Tefferi A
Lancet; 2003 Aug; 362(9383):535-6. PubMed ID: 12932387
[TBL] [Abstract][Full Text] [Related]
12. Growth-inhibitory effects of four tyrosine kinase inhibitors on neoplastic feline mast cells exhibiting a Kit exon 8 ITD mutation.
Hadzijusufovic E; Peter B; Rebuzzi L; Baumgartner C; Gleixner KV; Gruze A; Thaiwong T; Pickl WF; Yuzbasiyan-Gurkan V; Willmann M; Valent P
Vet Immunol Immunopathol; 2009 Dec; 132(2-4):243-50. PubMed ID: 19505729
[TBL] [Abstract][Full Text] [Related]
13. Mastocytosis: Moving the Field to Precision and Personalized Medicine.
Castells MC
Immunol Allergy Clin North Am; 2018 Aug; 38(3):xv-xvii. PubMed ID: 30007470
[No Abstract] [Full Text] [Related]
14. Juxtamembrane-type c-kit gene mutation found in aggressive systemic mastocytosis induces imatinib-resistant constitutive KIT activation.
Nakagomi N; Hirota S
Lab Invest; 2007 Apr; 87(4):365-71. PubMed ID: 17259998
[TBL] [Abstract][Full Text] [Related]
15. Mastocytosis: advances in diagnosis and treatment.
Hungness SI; Akin C
Curr Allergy Asthma Rep; 2007 Jul; 7(4):248-54. PubMed ID: 17547845
[TBL] [Abstract][Full Text] [Related]
16. Tyrosine kinase inhibitors in the treatment of systemic mastocytosis.
Ustun C; DeRemer DL; Akin C
Leuk Res; 2011 Sep; 35(9):1143-52. PubMed ID: 21641642
[TBL] [Abstract][Full Text] [Related]
17. Evolution of urticaria pigmentosa into indolent systemic mastocytosis: abnormal immunophenotype of mast cells without evidence of c-kit mutation ASP-816-VAL.
Noack F; Escribano L; Sotlar K; Nunez R; Schuetze K; Valent P; Horny HP
Leuk Lymphoma; 2003 Feb; 44(2):313-9. PubMed ID: 12688351
[TBL] [Abstract][Full Text] [Related]
18. Molecular response to imatinib in KIT F522C-mutated systemic mastocytosis.
Broderick V; Waghorn K; Langabeer SE; Jeffers M; Cross NCP; Hayden PJ
Leuk Res; 2019 Feb; 77():28-29. PubMed ID: 30612056
[No Abstract] [Full Text] [Related]
19. Identification of a c-kit exon 8 internal tandem duplication in a feline mast cell tumor case and its favorable response to the tyrosine kinase inhibitor imatinib mesylate.
Isotani M; Tamura K; Yagihara H; Hikosaka M; Ono K; Washizu T; Bonkobara M
Vet Immunol Immunopathol; 2006 Nov; 114(1-2):168-72. PubMed ID: 16908071
[TBL] [Abstract][Full Text] [Related]
20. [Systemic mastocytosis].
Fain O; Stirnemann J; Eclache V; Barete S; Casassus P; Hermine O; Lorholary O
Presse Med; 2005 May; 34(9):681-7. PubMed ID: 15988348
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
